Antiphospholipid antibodies and the antiphospholipid syndrome: An update on treatment and pathogenic mechanisms

Current Opinion in Hematology

Volumn 13, Issue 5, 2006, Pages 366-375

  Pierangeli, Silvia S ^a   Chen, Pojen P ^b   González, Emilio B ^c  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antiphospholipid antibodies; Complement activation; Intracellular signalling; Thrombosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DILAZEP; DORAMAPIMOD; ENOXAPARIN; FLUINDOSTATIN; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; RITUXIMAB; SERINE PROTEINASE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BLOOD CLOTTING; CELL MEMBRANE; CLINICAL FEATURE; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOCYTE; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; COMPLEMENT ACTIVATION; ENDOTHELIAL CELLS; HUMANS; THROMBOSIS;

EID: 33746741718     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000239710.47921.d2     Document Type: Review

References (95)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26:324-326.
2. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
3. 2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4124.
4. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306. This paper summarizes evidence-based revision of the preliminary consensus criteria of 1999.
5. Gleason CB, Stoddard MF, Wagner SG, et al. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin negative systemic lupus erythematosus. Am Heart J 1993; 125:1123-1129.
6. Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multisystem thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23:499-504.
7. Atsumi T, Furukawa O, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005; 14:499-504.
8. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipis syndrome. Am J Med 2000; 51:169-185.
9. Sherer Y, Hassin S, Shoenfeld Y, et al. Transverse myelitis in patients with antiphospholipid antibodies - the importance of early diagnosis and treatment. Clin Rheumatol 2002; 21:207-210.
10. Al-Matar M, Jaimes J, Malleson P. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 2000; 2:107-108.
11. Hughes GR. Migraine, memory loss, and 'multiple sclerosis' Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003; 79:81-83.
12. Mesa HA, Lang B, Schumacher M, et al. Sneddon's syndrome and phospholipid antibodies. Clin Rheumatol 1993; 12:253-256.
13. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 2005; 210:727-733.
14. Wiedermann FJ. Alveolar and serum antiphospholipid antibodies in acute respiratory distress syndrome associated with catastrophic antiphospholipid syndrome. Ann Rheum Dis 2006; 65:413.
15. Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. 'Black swan in the kidney': Renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002; 62:733-74416.
16. Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 1:61-78.
17. Khamashta MA, Cuadrado MJ, Mujic T, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332:993-997.
18. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 1997; 157:2101-2108.
19. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133-1138.
20. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848-853.
21. Rubenstein E, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33:355-357. This study underscored the value of using rituximab for the treatment of resistant APS.
22. Ahn ER, Lander G, Bidot CJ, et al. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005; 78:127-129. This study showed the benefits of the treatment with rituximab on long-term remission of APS-related clinical symptoms.
23. Tomietto P, Gremese E, Tolulsso B, et al. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 2004; 92:1150-1153.
24. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41:924-929.
25. Ho KT, Ahn W, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombosis events. Rheumatology 2005; 44:1303-1307.
26. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380-4384.
27. Espinola RG, Pierangeli SS, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG Antiphospholipid antibodies. Thromb Haemost 2002; 87:518-522.
28. Branch DW, Dudley DJ, Mitchell MD, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163:210-216; 10-14.
29. Pierangeli SS, Liu XW, Anderson GH, et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74:1361-1367.
30. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99:1997-2000.
31. 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101:157-162.
32. Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7:S114-S119.
33. Simantov E, LaSala J, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-2219.
34. 2glycoprotein I and induce endothelial cell activation. Arthritis Rheum 1997; 40:551-561.
35. Gharavi AE, Pierangeli SS, Colden-Stanfield M, et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163:2922-2927.
36. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84:388-395.
37. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88:245-250.
38. Espinola RG, Liu X, Colden-Stanfield M, et al. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002; 1:843-848.
39. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43:55-64.
40. Forastiero RR, Martinuzzo ME, De Larranaga G. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 2005; 14:129-136.
41. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40:834-841.
42. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79:276-281.
43. Dobado-Barrios M, Lopez-Perrara C, Velasco F, et al. Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82:1578-1582.
44. Martini F, Farsi A, Gori AM, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 1996; 5:206-211.
45. Zhou H, Woldberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104:2353-2358.
46. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (antib2glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44:2870-2878.
47. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48:3272-3279.
48. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2:1558-1563.
49. 2glycoprotein I antibodies. Thromb Haemost 2002; 88:851-857.
50. Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52:1545-1554. This publication shows for the first time that upregulation of tissue factor in endothelial cells induced by aPL antibodies involves p38 MAPK phosphorylation.
51. 2glycoprotein I antibodies. Int Immunol 2004; 16:1632-1641.
52. López-Pedrera C, Buendia P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54:301-1153.
53. 2glycoprotein I antibodies. J Immunol 1998; 160:5572-5578.
54. 2glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem 2000; 275:15541-15548.
55. 2GPI.
56. Meroni PL, Tincani A, Sepp N, et al. Endothelium and the brain in CNS lupus. Lupus 2003; 12:1-10.
57. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101:3495-3500.
58. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll like receptor 4 is involved in in vivo antiphospholipid-mediated thrombosis and endothelial cell activation [abstract]. Blood 2005; 106:43a.
59. Schroder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5:156-164.
60. 2glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 20. J Biol Chem 2003; 278:33831-33838.
61. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73:529-534.
62. Arvieux J, Rousell B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to b2glycoprotein I. Thromb Haemost 1993; 70:336-341.
63. 2-glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79:42-45.
64. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid Antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70:667-671.
65. Khamashta MA, Harris EN, Gharavi AE, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47:849-854.
66. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73:529-534.
67. 2glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the Antiphospholipid Syndrome. J Rheumatol 1998; 25:51-56.
68. 2gycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 2003; 30:55-58.
69. Lin YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80:3135-3143.
70. Wang L, Su C-Y, Chou K-Y, Wang CT. Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies. Br J Haematol 2002; 118:1152-1162.
71. Vega-Ostertag ME, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50:2911-2919.
72. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004; 114:467-476.
73. Barone FC, Irving EA, Ray AM, et al. Inhibition of p38 mitogen-activated-protein kinase provides neuroprotection in cerebral focal ischemis. Med Res Rev 2001; 21:129-145.
74. Dumas J, Smith RA, Lowinger TB. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Devel 2004; 7:600-616.
75. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase. In animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279:1453-1461.
76. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101:4446-4448.
77. Holers VM, Girardi G, Mo L, et al. C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-220.
78. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002; 61:46-50.
79. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest 2003; 112:1644-1654.
80. Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine 2004; 10:1222-1226.
81. Pierangeli SS, Girardi G, Vega-Ostertag ME, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52:2120-2124. This study showed that aPL-induced thrombosis involves complement activation.
82. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to b2-glycoprotein I is complement-dependent and requires a priming factor. Blood 2005; 106:2340-2346. This excellent publication confirms, utilizing outstanding experimental approaches, that complement activation is required in aPL-mediated thrombosis. The authors utilized endotoxin to trigger thrombosis.
83. Carbone J, Oerra M, Rodriguez-Mahou M, et al. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999; 8:274-278.
84. Munakata Y, Saito T, Matsuda K, et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000; 83:728-731.
85. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 1992; 10:455-460.
86. Olee TW, Pierangeli SS, Handley HH, et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci USA 1996; 93:8606-8611.
87. Zhu M, Olee T, Le DT, et al. Characterization of IgG monoclonal anti cardiolipin/antib2GP1 antibodies from two patients with the antiphospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105:102-109.
88. Zhao Y, Rumold R, Ahmed AE, et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999; 42:2132-2138.
89. Hwang K, Grossman J, Visvanathan S, et al. Identification of antithrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167:7192-7198.
90. Hwang KK, Yang CD, Yan W, et al. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48:1622-1630.
91. Yang CD, Hwang KK, Yan W, et al. Identification of antiplasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172:5765-5773.
92. Lu CS, Horizon AA, Hwang KK, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005; 52:4018-4027.
93. Borrell M, Sala N, Castellanau C, et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68:268-272.
94. Kolev K, Gombas J, Varadi B, et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002; 87:502-508.
95. Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: of tPA in 2 patients. Blood 2004; 103:2121-2126.